Evidence map›Paper›PMID 37874311›Full record

ArticleJournal of feline medicine and surgery2023

Evaluation of gastroprotectant administration in hospitalized cats in a tertiary referral hospital.

Tarini V Ullal, Stanley L Marks, Janny V Evenhuis, Monica E Figueroa, Leah K Pomerantz, Lauren R Forsythe

Open access · diamondAbstract read
In one paragraph

Article in Journal of feline medicine and surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tarini V UllalDepartment of Medicine and Epidemiology, University of California-Davis School of Veterinary Medicine, Davis, CA, USA.
Stanley L MarksDepartment of Medicine and Epidemiology, University of California-Davis School of Veterinary Medicine, Davis, CA, USA.ORCID 0000-0001-7991-702X
Janny V EvenhuisDepartment of Medicine and Epidemiology, University of California-Davis School of Veterinary Medicine, Davis, CA, USA.ORCID 0000-0003-2953-376X
Monica E FigueroaDepartment of Medicine and Epidemiology, University of California-Davis School of Veterinary Medicine, Davis, CA, USA.
Leah K PomerantzDepartment of Medicine and Epidemiology, University of California-Davis School of Veterinary Medicine, Davis, CA, USA.
Lauren R ForsytheDepartment of Veterinary Clinical Medicine, University of Illinois College of Veterinary Medicine, Urbana, IL, USA.
University of California, Davis · USNew England Disabled Sports · USUniversity of Illinois Urbana-Champaign · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe primary objective of this study was to evaluate the prescription patterns and appropriateness of the use of gastroprotectant medication in cats.

methodsPharmacy dispensation logs from an academic tertiary referral center were reviewed between 1 January 2018 and 31 December 2018. Cats that were administered proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), sucralfate, misoprostol, antacids or a combination were included. Data regarding medication, dosage, formulation, duration of administration, completeness of discharge instructions and clinical rationales for administration were obtained from medical records. The appropriateness of gastroprotectant use was assessed according to the American College of Veterinary Internal Medicine consensus statement guidelines.

resultsOf the 110 cases, 67 (60.9%) were prescribed a gastroprotectant medication without an appropriate indication. The most common reason for prescription was acute kidney injury in 26/67 (38.8%). PPIs were the most common gastroprotectant medication administered in 95/110 (86.3%) cats, followed by sucralfate in 18/110 (16.4%) and H2RAs in 11/110 (10%). Of the 35 cases in which gastroprotectant therapy was indicated, the medication chosen or dosage administered was considered suboptimal in 16 (45.7%). Instructions regarding the duration of administration, potential adverse effects and timing of administration in relation to meals or other medications were inconsistently provided in discharge instructions to pet owners. Of the 29 cases discharged with omeprazole, only 13 (44.8%) instructions included a duration of administration, while 6 (20.7%) recommended continuing gastroprotectants indefinitely until further notice, 16 (55.2%) discussed the timing of the administration in relation to a meal and six (20.7%) mentioned potential adverse effects; none advised tapering of omeprazole before discontinuation. CONCLUSIONS AND RELEVANCE: When prescribed, gastroprotectant medications were frequently prescribed injudiciously to cats in this referral population over a 12-month period. Discharge instructions to pet owners also often lacked information and recommendations regarding optimal administration, potential adverse effects, and tapering or discontinuation of the medications.

Indexed as

Proton Pump InhibitorsSucralfateAnimalsCatsHistamine H2 AntagonistsHumansOmeprazoleTertiary Care CentersUnited StatesHistamine H2 AntagonistsOmeprazoleProton Pump InhibitorsSucralfateAcid suppressanterosionfamotidinegastrointestinal ulcerhistamine-2 receptor antagonistomeprazole, pantoprazoleproton pump inhibitorsucralfate

Identifiers

PMID37874311
PMCPMC10812023
OpenAlexW4387893186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.